The Discovery of Purine-Based Agents Targeting Triple-Negative Breast Cancer and the αB-crystallin/VEGF Protein–protein Interaction

Medicinal Chemistry Research - United States
doi 10.1007/s00044-018-2275-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Targeting MYC for Triple-Negative Breast Cancer Treatment

Oncoscience
Cancer ResearchOncology
2018English

Development of a Vaccine Targeting Triple-Negative Breast Cancer

2013English

Targeting DNA Methylation for Treating Triple-Negative Breast Cancer

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2019English

The Matrix Protein Fibulin-3 Promotes KISS1R Induced Triple Negative Breast Cancer Cell Invasion

Oncotarget
Oncology
2018English

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Triple-Negative Breast Cancer

2018English

Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2015English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Elevated Levels of eEF1A2 Protein Expression in Triple Negative Breast Cancer Relate With Poor Prognosis

PLoS ONE
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy